Atossa Therapeutics - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים ATOS

Atossa Therapeutics develops targeted breast cancer therapies, leveraging patent protection amidst costly R&D expenditures. The monetization of unique formulas ensures long-term demand for its drugs. The current year-over-year revenue growth rate (TTM) is recorded at 0.00, confirming the company's financial momentum. Looking ahead, Atossa Therapeutics plans to complete clinical phases and secure a major licensing partner.

For Atossa Therapeutics (ATOS), whose success depends on Endoxifen clinical trials within the defensive oncology sector, the TTM annual revenue growth serves as an indicator of development commercialization. This metric compares revenue over the last twelve months with the same period last year, allowing investors to filter out market noise and avoid freezing capital in the event of negative fundamental sales trends.